Clinical Trials Sponsored by BeiGene, Ltd.

Total 18758 results

Celgene

Completed

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Primary Myelofibrosis | Anemia

United States, France, Italy, United Kingdom
Celgene

Completed

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

Multiple Myeloma

United States
Celgene

Terminated

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Beta Thalassemia Intermedia | Beta Thalassemia Major

France, United Kingdom, Italy, Greece
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
Celgene

Completed

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

United States, Austria, United Kingdom, Estonia, Denmark
Celgene

Active, not recruiting

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Glioblastoma

Spain, United States, Denmark, Italy, Netherlands, Norway, Sweden
Celgene

Terminated

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Leukemia, Myeloid

United States, France, Belgium, Spain
Celgene

Completed

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Canada, Spain, United Kingdom, United States, France, Austria, Germany, Italy, Netherlands, Belgium, Portugal, Poland
Celgene

Terminated

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Carcinoma, Squamous Cell

United States
Celgene

Completed

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) (POM Renal)

Multiple Myeloma | Renal Impairment

United States, Canada
Celgene

Completed

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Multiple Myeloma

Belgium, United Kingdom, Italy, Germany, Sweden, Denmark, Norway, Spain
Celgene

Completed

Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

Myelodysplastic Syndromes | Beta-thalassemia

Austria
Celgene

Completed

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Multiple Myeloma

United States, Japan
Celgene

Completed

Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy (DD-CMM)

Breast Neoplasms

Spain
Celgene

Completed

An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice (MIROIR)

Multiple Myeloma

France
Celgene

Completed

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

Liver Diseases | Digestive System Diseases

United States
Celgene

Completed

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Myelodysplastic Syndromes | Multiple Myeloma

Japan
Celgene

Completed

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Multiple Myeloma

Japan
Celgene

Completed

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

France, Spain
Celgene

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

Healthy Volunteers

United States
Celgene

Withdrawn

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Lymphoma, B-Cell

Korea, Republic of, United States, Spain, Belgium, Taiwan, United Kingdom, Austria, France
Celgene

Completed

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene

Completed

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (ENHANCE)

Leukemia, Lymphocytic, Chronic, B-Cell

Spain, United States, Italy, Germany, Austria
Celgene

Completed

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

Korea, Republic of, United States, Belgium, Israel, Netherlands, Australia, Germany, Hungary, New Zealand, Italy, Canada, Bulgaria, Croatia, United Kingdom, Argentina, Austria, Belarus, Czechia, Georgia, Moldova, Republic of, Po... and more
Celgene

Terminated

A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis

Psoriasis | Healthy Volunteers

Germany
Celgene

Completed

A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance (MIR50)

Multiple Myeloma

Spain
Celgene

Completed

A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects

Healthy Volunteer

China
Celgene

No longer available

Expanded Access for Marizomib

Solid Tumor

United States
Celgene

Completed

Treatment of Pancreatic Cancer With Abraxane

Metastatic Pancreatic Cancer

Austria
Celgene

Completed

Japanese Pharmacokinetic Bridging Study for CC-93538

Healthy Volunteers

United States
Celgene

Completed

Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites

Healthy Volunteers

United States
Celgene

Completed

Relative Bioavailability Study of CC-292

Healthy Volunteers

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Celgene

Completed

An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide. (REVIEW)

Multiple Myeloma
Celgene

Completed

Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort

Hepatic Insufficiency

United States
Celgene

Completed

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Melanoma | Sarcoma | Neoplasms | Lymphoma | Renal Cell Carcinoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia | Breast Cancer | Small Cell Lung Cancer | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Non-Small Cell Lung Cancer | Osteosarcoma | Glioblastoma Multiforme | Metastatic Breast... and other conditions

United States
Celgene

Completed

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Chronic Lymphocytic Leukemia

United States
Celgene

Completed

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

Healthy Volunteer

United States
Celgene

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

Healthy Volunteer

United States
Celgene

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

Healthy Volunteer

United States
Celgene

Completed

Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults

Healthy Volunteers

United States
Celgene

Completed

ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Celgene

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects

Healthy Volunteer

United Kingdom
Celgene

Completed

Longterm Follow-up of Subjects Treated With bb2121

Multiple Myeloma

United States
Celgene

Completed

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid

United States, Canada
Celgene

Completed

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Leukemia Lymphocytic Chronic B-Cell

United States, Austria
Celgene

Completed

A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.

Leukemia, Myeloid, Acute

Germany, Netherlands, Denmark
Celgene

Terminated

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Terminated

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Stage IV (Metastatic) Breast Cancer

United States

3

Subscribe